CMS and FDA announce RAPID Coverage Pathway to accelerate patient access to breakthrough medical devices
Summary
The Centers for Medicare and Medicaid Services and FDA jointly announced the RAPID (Rapid Access Pathway for Innovative Devices) Coverage Pathway in late April 2026, designed to significantly accelerate the period between FDA clearance/approval and CMS national coverage determination for breakthrough medical devices. Under RAPID, devices with FDA Breakthrough Device Designation can receive concurrent CMS coverage review during FDA evaluation rather than the typical 1-3 year wait after FDA approval. The pathway has major implications for BCI companies including Neuralink, Synchron, CorTec, and ONWARD Medical, all of which hold Breakthrough Device designations.
Why it matters
The gap between FDA approval and CMS coverage has been the primary commercial bottleneck for innovative medical devices — companies receive FDA clearance but then wait years for the reimbursement that enables hospital adoption. RAPID eliminating this gap could compress the timeline from FDA approval to commercial revenue by 18-36 months for every BCI company with Breakthrough Device Designation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial